USPTO serial 79180936
ORPHAZYME
Reviewed by CopyMark Law Group
Reg. 5139414Status 404
- Filing date
- Status date
- Registration date
- Feb 14, 2017
- Examiner
- LEE, DOUGLAS
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ORPHAZYME?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
DK-2200 København N, DK
DK-2200 København N, DK
DK
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John Paul Oleksiuk
John Paul Oleksiuk Cooley LLP1299 Pennsylvania Avenue, NW, Suite 700Washington, DC 20004UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry and in science; proteins for use in science and in manufacture; biochemicals, namely, polypeptides for scientific, research and commercial use; with the exclusion of chemicals used in the food industry and animal food industry and ingredients for foodstuffs for animals | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceutical and medical preparations for the treatment of rare and genetic diseases, for the treatment of diseases involving protein misfolding, for the treatment of diseases involving lysosomal pathology, for the treatment of disorders of the central nervous system, for the treatment of neurodegenerative diseases, for the treatment of neuropsychiatric disorders, for the treatment of movement disorders, for the treatment of parkinsonism and Parkinson's disease, for the treatment of Amyotrophic lateral sclerosis (ALS), motor neuron disease (MND) and Lysosomal storage diseases (LSD) and for the treatment of Niemann-Pick disease type C, for the treatment of diseases associated with dysregulation of cholesterol homeostasis, cholesterol trafficking, cholesterol metabolism and cholesterol biosynthesis and for the treatment of atherosclerosis; chemical-pharmaceutical preparations for the treatment of rare and genetic diseases, for the treatment of diseases involving protein misfolding, for the treatment of diseases involving lysosomal pathology, for the treatment of disorders of the central nervous system, for the treatment of neurodegenerative diseases, for the treatment of neuropsychiatric disorders, for the treatment of movement disorders, for the treatment of parkinsonism and Parkinson's disease, for the treatment of Amyotrophic lateral sclerosis (ALS), motor neuron disease (MND) and Lysosomal storage diseases (LSD) and for the treatment of Niemann-Pick disease type C, for the treatment of diseases associated with dysregulation of cholesterol homeostasis, cholesterol trafficking, cholesterol metabolism and cholesterol biosynthesis and for the treatment of atherosclerosis; diagnostic preparations for medical purposes; reagents for medical purposes and for research; preparations for analysis for medical and research purposes for the treatment of rare and genetic diseases, for the treatment of diseases involving protein misfolding, for the treatment of diseases involving lysosomal pathology, for the treatment of disorders of the central nervous system, for the treatment of neurodegenerative diseases, for the treatment of neuropsychiatric disorders, for the treatment of movement disorders, for the treatment of parkinsonism and Parkinson's disease, for the treatment of Amyotrophic lateral sclerosis (ALS), motor neuron disease (MND) and Lysosomal storage diseases (LSD) and for the treatment of Niemann-Pick disease type C, for the treatment of diseases associated with dysregulation of cholesterol homeostasis, cholesterol trafficking, cholesterol metabolism and cholesterol biosynthesis and for the treatment of atherosclerosis; all of the aforementioned with the exclusion of veterinary preparations and ingredients, supplements for food, and medicated foodstuffs for animals | SECTION 71 - CANCELLED | — |
| 042 | Industrial analysis and research services; basic research and clinical research, hereunder for medicine and vaccine development; all the aforementioned services with the exclusion of services relating to the veterinary sector | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Orphazyme ApS
- Other trademarks owned by Orphazyme ApS
- Other trademarks owned by Orphazyme A/S
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named ORPHAZYME
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 25, 2026 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Jun 25, 2026 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Apr 25, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 27, 2024 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| May 6, 2024 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| May 6, 2024 | INPC | INVALIDATION PROCESSED | — |
| Apr 25, 2024 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Aug 25, 2023 | C71T | CANCELLED SECTION 71 | — |
| Jul 10, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 14, 2022 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jun 12, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 8, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 8, 2021 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jun 8, 2021 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Jun 8, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 8, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 5, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 5, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 5, 2021 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| May 5, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 5, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 5, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jan 25, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 25, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 7, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 30, 2018 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Aug 31, 2017 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 23, 2017 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 1, 2017 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jun 1, 2017 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 14, 2017 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 2, 2017 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 14, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 22, 2016 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 29, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 29, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 9, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 22, 2016 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 18, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 5, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 5, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 2, 2016 | ALIE | ASSIGNED TO LIE | — |
| Sep 26, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 13, 2016 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 28, 2016 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 28, 2016 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 26, 2016 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 25, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 25, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 21, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 2, 2016 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 28, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 21, 2016 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |